10 Stocks Under $10 that Will Triple

2. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Upside Potential: 406.94%

Number Of Hedge Funds: 44

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial biotech company with a focus on autologous tumor-infiltrating lymphocyte (TIL) therapies. These therapies target metastatic melanoma and other solid tumor cancers. The company’s pipeline includes Amtagvi, an FDA-approved T-cell therapy for advanced melanoma, and Proleukin, an interleukin-2 product used to treat cancer. Iovance is pushing forward with lifileucel and LN-145 for non-small cell lung cancer and gynecological cancers, along with next-gen TIL therapies in clinical trials.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) showed solid performance in 2024 as its total product revenue hit $164.1 million, reaching the top end of its guidance. Amtagvi brought in $103.6 million, showing strong early adoption, while Proleukin added another $60.5 million. In Q4 alone, revenue was $73.7 million, with Amtagvi accounting for $48.7 million. For 2025, the company predicts product revenue between $450-475 million, driven by higher demand, more treatment centers, and continuous adoption.

Furthermore, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is growing globally as regulatory filings for Amtagvi are under review in the U.K., EU, and Canada, with approvals expected in 2025. The company is also running clinical trials for advanced melanoma and certain lung cancers that have not responded to immunotherapy, which could expand Amtagvi’s potential uses. Additionally, the company’s cell therapy plant expansion will soon support over 5,000 patients yearly.

Thus, with an expanded revenue base, market reach, and solid clinical progress, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ranks among the stocks that will triple.